LB Pharmaceuticals Inc LBRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -959.39% | -259.10% | -126.23% | 74.92% | 82.41% |
| Total Depreciation and Amortization | 27.63% | 3.80% | 6.25% | 1,520.00% | 2,433.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,152.47% | 1,943.18% | 29.26% | 118.41% | -78.80% |
| Change in Net Operating Assets | 760.64% | -143.81% | -234.27% | 99.03% | -112.79% |
| Cash from Operations | -571.47% | -186.54% | -219.56% | 84.69% | 64.48% |
| Capital Expenditure | -4,133.33% | -52.38% | 83.19% | 100.00% | 121.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -252.94% | -100.00% |
| Cash from Investing | 888.89% | -100.64% | -100.30% | -255.28% | -99.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 1,639,885.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 1,518,560.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -571.30% | 2,339.80% | -345.31% | 3,626.45% | 37.05% |